|
|
|
| Experimental study of estrogen antagonist combined with celecoxib in the treatment of rabbit with knee joint traumatic myositis ossificans |
| HAN Feng1 LU Cheng-hua2 YI Li2 JIANG Hong1 |
1.The Second Department of Orthopaedics,Dalian Friendship Hospital,Liaoning Province,Dalian 116001,China;
2.Department of Orthopedics,Dalian Friendship Hospital,Liaoning Province,Dalian 116001,China |
|
|
|
|
Abstract Objective To investigate preventive effect of estrogen antagonist Tamoxifen combined with Celecoxib in the rabbit with knee joint traumatic myositis ossificans.Methods 30 rabbits were randomly divided into group A,B and C, traumatic myositis ossificans model of knee joint were make with knee joint fixed after strong passive stretch and violent massage,and rabits in group A were given the normal saline B were treated with Tamoxifen and Celecoxib and the group C were treated with Tamoxifen and Celecoxib,rabits in the group,all rabits were treated for 9 weeks.The swelling degree of knee joint were compared among three groups at 1,5,9 weeks after making model,degree of myositis ossificans were compared among three groups at 5,9 weeks after making model.Results Circumference of knee joint at 1 week after making model than was larger than before making model among three groups (group A:t=7.14,P=0.000;group B:t= 5.29,P=0.000;group C:t=4.86,P=0.001),and the group A was larger than that of the group C (t=3.96,P=0.002)and group B(t=3.57,P=0.003),and the group C was less than that of the group B(t=2.48,P=0.007);circumference of knee joint 5 week after making model was less than 1 week after making model among three groups(group A:t=3.26,P=0.005;group B:t= 2.94,P=0.004;group C:t=2.58,P=0.004),circumference of knee joint in group A was larger than that in the group B (t= 5.19,P=0.000)and group C(t=6.10,P=0.000),and the group B was larger than that in group C(t=2.84,P=0.003);9 week after making model,circumferences of knee joint of group A and group B were larger than those at 5 weeks after making model(group A:t=1.96,P=0.010;group B:t=1.84,P=0.013),and the group C was less than that at 5 weeks after making model(t=2.29,P=0.008),circumference of knee joint of the group A was larger than that in the group C(t=3.82,P=0.001) and group B(t=3.14,P=0.002),and group C was less than that in the group B(t=4.29,P=0.000).Degree of myositis ossificans at 5,and 9 week after making model was different among three groups(5 weeks:H=7.29,P=0.001,9 weeks:H=17.16, P=0.000),and degree of myositis ossificans in group B and group C was lower than that in the group A at different time point(group B,5 weeks:U=4.26,P=0.004,9 weeks:U=8.46,P=0.000;group C,5 weeks:U=5.14,P=0.002,9 weeks:U=9.17,P=0.000),and group C was lower than that in the group B(5 weeks:U=4.26,P=0.004,9 weeks:U=4.89,P=0.003).Conclusion Estrogen antagonist Amoxifen combined with Celecoxib can effectivly control the progress of myositis ossificans,and improve effect of prevention.
|
|
|
|
|
|
| [1] |
Nunley RM，Zhu J，Clohisy JC，et al.Aspirin decreases heterotopic ossification after hip resurfacing[J].Clin Orthop Relat Res，2011，469（6）：1614-1620.
|
| [2] |
王建，王斌，糜漫天，等.雌马酚对大鼠成骨细胞增殖和分化的影响[J].武警医学院学报，2009，18（12）：1050-1054.
|
| [3] |
邓柏杰，陈渭良，张继平，等.家兔膝关节创伤性骨化性肌炎动物模型的建立[J].中国骨伤，2000，13（2）：80-82.
|
| [4] |
张磊，李然伟，洪宝发，等.塞来昔布对VX2兔肾癌的抑制作用[J].解放军医学杂志，2005，30（12）：1086-1087.
|
| [5] |
王巍，郝立君，王洁，等.他莫昔芬对兔耳增生性瘢痕作用的实验研究[J].黑龙江医学，2005，29（11）：821-823.
|
| [6] |
周明旺，李盛华.创伤性骨化性肌炎的诊疗现状[J].中国中医骨伤杂志，2009，17（4）：67-69.
|
| [7] |
王丹彤，赵文海，李权忠，等.骨化性肌炎的分期治疗[J].吉林医药，2007，29（7）：38-39.
|
| [8] |
刘俊峰，潘敏鸿，张智弘.运动损伤所致骨化性肌炎临床与病理分析[J].江苏医药，2013，41（6）：647-649.
|
| [9] |
高杰，桂斌捷，胡孔足，等.塞来昔布对人成骨细胞增殖的影响及其作用机制[J].安徽医科大学学报，2015，50（5）：608-609.
|
| [10] |
胡萍.塞来昔布治疗膝骨关节炎疗效观察[J].中国当代医药，2011，18（22）：58-59.
|
| [11] |
黄凯伟.塞来昔布治疗膝关节骨性关节炎的临床观察[J].中国医药导报，2009，6（31）：51-52.
|
| [12] |
隋国良，彭依群，翟木绪，等.雌二醇下调人成骨细胞CTGF表达的信号转导机制研究[J].中国骨质疏松杂志，2006，12（5）：443-446.
|
| [13] |
苏欣，廖二元，朱旭萍，等.雌二醇对人成骨细胞护骨素、护骨素配体及其相关因子的调节[J].中华老年医学杂志2004，23（3）：153-156.
|
| [14] |
韦竑宇，梁立.他莫昔芬对大鼠脊髓损伤后炎性反应及细胞凋亡的影响[J].中国医药导报，2014，11（34）：23-26.
|
| [15] |
李万根.雌激素拮抗剂与骨质疏松[J].国际内分泌代谢杂志，1998，8（2）：71-74.
|
|
|
|
